Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.77 |
| ▸ | F2 | P00734 | 11/20 | 0.77 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 10/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 10/20 | 0.77 |
| ▸ | F9 | P00740 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7398441 | 0.85 | F10 (0.69) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3830234 | 0.85 | F10 (0.74) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3829898 | 0.84 | F10 (0.77) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3831605 | 0.83 | F10 (0.76) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3831563 | 0.83 | F10 (0.75) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3834915 | 0.83 | F10 (0.76) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3831566 | 0.83 | F10 (0.74) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3834842 | 0.82 | F10 (0.73) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7449535 | 0.81 | F10 (0.81) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3831557 | 0.81 | F10 (0.72) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | claimed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | claimed |
| EP-0946508-B1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-09-23 | — | — | EP | disclosed |
| US-6548512-B1 | Pyrazole derivatives such as 1-(3-amidinophenyl)-3-methyl-2-((5-(2'-aminosulfonylphenyl-1-yl)pyrimidin-2 -yl)aminocarbonyl)pyrazole; treating thromboembolic disorders | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-6020357-A | CARDIOVASCULAR DISORDERS; ANTCOAGULANTS | DUPONT PHARMACEUTICALS COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0946508-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | Du Pont Pharmaceuticals Company (US) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998028269-A1 | NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-07-02 | — | — | WO | disclosed |